STOCKHOLM, SWEDEN – September 2, 2020. Karolinska Development (Nasdaq Stockholm: KDEV) announces that its portfolio company Umecrine Cognition will present the results from its recently conducted clinical phase 2a study of the drug candidate golexanonole, that is in clinical development for hepatic encephalopathy. The results will be presented at The Liver Meeting Digital Experience™ on November 13–16, 2020.
Umecrine Cognition’s drug candidate golexanolone, a novel orally-active GABAA receptor modulating steroid antagonist, is targeting the debilitating symtoms of hepatic encephalopathy (HE). Following a recently conducted clinical phase 2a study, the company will present the results at The Liver Meeting, one the world’s largest conferences in the field of hepatic medicine. Prior to the meeting, Umecrine Cognition’s scientific abstract of the study results has been ranked in the top 10 percent, and selected as a “Poster of Distinction”, and will receive special recognition by AALSD.
“We are glad that the results from Umecrine Cognition’s clinical study are received with such interest and that the company is being noticed as an important actor at one of the largest conferences in the field”, says Viktor Drvota, CEO Karolinska Development.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com
Attachment
